AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Argenx surges after hit in nerve disorder
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Caribou’s allogeneic Car meets a six-month bar
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
A chronic disappointment for Viridian
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.